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Aim: Early intervention programs for first-episode psychosis have led to the aware-
ness that the period before onset of a first episode is important in light of early inter-
vention. This has induced a focus on the so-called ‘at risk mental state’ (ARMS).
Individuals with ARMS are at increased risk for later psychotic disorder, but also for
other psychiatric disorders as well as poor psychosocial functioning. Thus, adequate
detection and treatment of ARMS is essential.
Methods: Since 2018, screening for and treatment of ARMS is recommended stan-
dard care in the Netherlands. Implementation is still ongoing. We initiated a naturalis-
tic long-term cohort study of ARMS individuals, the onset and transition of and
recovery from adverse development (OnTheROAD) study, with the aim to monitor
course and outcome of symptoms and psychosocial functioning over time, as well as
patterns of comorbidity and associations with factors of risk and resilience. To this
end, participants complete a broad battery of instruments at baseline and yearly
follow-up assessments up to 3 years. Outcome is defined in terms of symptom sever-
ity level, functioning and quality of life. In particular, we aim to investigate the impact
of negative symptoms as part of the ARMS concept. Results from this study can aid in
refining the existing ARMS criteria, understanding the developmental course of ARMS
and investigating the hypothesized pluripotentiality in outcome of ARMS. New knowl-
edge may inform the further development of specialized early interventions.
Results and Conclusions: In this article, we describe the rationale, outline and set-up
of OnTheROAD.
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1 | INTRODUCTION
Clinicians and researchers are still searching for valid diagnostic tools
to select optimal interventions and accurately predict course and out-
come of early psychopathological expressions (Kapur, Philips, & Insel,
2012). The current classification system based on the diagnostic and
statistical manual of mental disorders (DSM-5, American Psychiatric
Association, 2013) has, similarly to its predecessors, shortcomings in
these respects (Frances & Widiger, 2012; Kendell & Jablensky, 2003;
Kendler, Zachar, & Craver, 2011). Therefore, a different perspective
on psychopathology is needed, recognizing that psychological symp-
toms do not keep to the boundaries of diagnostic categories, do not
emerge out of the blue but often develop from precursor stages, and
vary greatly between individuals (McGorry, 2007; McGorry, Hickie,
Yung, Pantelis, & Jackson, 2006; McGorry & van Os, 2013). In recent
years, the concept of clinical staging was introduced (McGorry et al.,
2006), promoting a subtler, more differentiated addition to the diag-
nostic process, studying the development of psychopathological
processes in individuals. The fundamental idea of this model, devel-
oped in the context of psychosis, is that different stages of psycho-
pathological development (ie, with increasing psychopathological
severity) can be distinguished that require different types of inter-
ventions that are effective specifically in that stage (McGorry
et al., 2006).
Psychotic disorders are considered among the most severe mental
disorders, in terms of both individual and societal burden (van Os &
Kapur, 2009). Therefore, early detection and treatment of psychosis
should be highly prioritized (McCrone, Patel, Knapp, & Lawton-Smith,
2008; McGorry, Killacky & Yung, 2007). Early intervention programs
for first-episode psychosis have led to the awareness that the period
before onset of such a first episode is very important in light of early
intervention. This period is often dubbed ‘prodromal phase’ retrospec-
tively after onset of a psychotic episode (Yung et al, 2003). However,
a broad line of research has shown that its clinical picture, character-
ized by psychological distress, attenuated psychotic symptoms (APS)
and a broad spectrum of other psychiatric symptoms, can also be
identified as a prospective risk factor (Yung et al, 2003). From this per-
spective, it is labelled rather as ultra high risk phase, clinical high risk
phase or at risk mental state (ARMS), indicating that, although this
population is at risk for developing more severe illness, adverse devel-
opment is not necessarily unavoidable.
Initially, ARMS was mainly investigated as predictor of later psy-
chotic disorder, with about 36% of the ARMS population developing a
first psychotic episode within 3 years of follow-up (Fusar-Poli et al.,
2012). There is an ongoing discussion on the predictive specificity of
ARMS. Although ARMS has been shown to be specific in its prediction
of later psychosis (Fusar-Poli et al., 2017; Woods et al., 2018), it has
also been suggested that ARMS has additional importance as a predic-
tor for a broader spectrum of adverse development in terms of both
(persistent) non-psychotic symptomatology and impaired functioning
(Yung et al., 2012), stressing the suggested pluripotent nature
of ARMS (McGorry, Hartmann, Spooner, & Nelson, 2018). This
pluripotentiality-hypothesis implies that earlier expressions of psycho-
pathology can be transient, persist or develop into a variety of clinical
disorders (McGorry et al., 2018). For example, early psychotic symp-
toms have been shown to predict the development of later psychotic
disorder (Poulton et al., 2000; Welham et al., 2009), but also of other
later (eg, mood) disorders (Addington et al., 2011; Fusar-Poli et al.,
2012; Kaymaz et al., 2012; Lin et al., 2015; McGrath et al., 2016;
Werbeloff et al., 2012) and/or impaired psychosocial functioning
(Addington et al., 2011). Part of these complex associations may be
explained by the fact that, although the definition of ARMS currently
relies heavily on positive psychotic symptomatology, presence of
other symptoms (eg, anxiety, depression) is very common (Yung et al,
2007; Lin et al., 2015). In addition to serving as an indicator of severe
mental health problems, early psychotic symptoms are also related to
current and future poor functional outcome (Cotter et al., 2014,
2018). Both types of outcome are equally important, but are not nec-
essarily identical: functional impairments can occur without noticeable
symptomatic impairments and vice versa (Lin, Wood, & Yung, 2013;
Verma, Subramaniam, Abdin, Poon, & Chong, 2012; Wunderink,
Sytema, Nienhuis, & Wiersma, 2009).
To better understand the nature and course of ARMS over time as
well the factors that may impact on this course, a broader assessment
of the clinical presentation in terms of both symptomatology and
functioning is needed. Individual risk profiling within this broader pic-
ture might help differentiate between individuals at highest risk of
poor outcome and individuals with highest chance of recovery. Since
2018, screening for as well as monitoring and treatment of ARMS are
included in the recommended standard care in the Dutch mental
health care system. We have been successful in implementing these
new procedures in the North of the Netherlands and are now setting
up a study to follow a cohort of individuals identified according to
these new procedures: the Onset and Transition of and Recovery
from Adverse Development (OnTheROAD) study. This project is in
line with other initiatives to follow cohorts of individuals at ARMS
(see eg, Brewer et al., 2006; Deriu, Moro, & Benoit, 2018 for over-
views of such cohorts). The regular guidelines are limited almost
exclusively to positive symptoms of psychosis and functioning. In
OnTheROAD, the goal is to assess individuals with ARMS from a
broader perspective, capturing multiple domains of psychopathology,
functioning, and factors of risk and resilience. In particular, we are
interested in the role of negative symptoms in ARMS (Wunderink,
2017), as these symptoms are increasingly acknowledged as important
predictors of both clinical (Pisculic et al., 2012; Demjaha, Valmaggia,
Stahl, Byrne, & McGuire, 2010) and functional (Kim et al., 2013; Lin
et al., 2011; Yung et al, 2019) outcome. The specific aim is to investi-
gate the added value of negative symptoms as a possible extension of
current ARMS criteria. Broadening the set of clinical measures and
factors of risk and resilience that may determine outcomes of ARMS
enables individual risk profiling and the investigation of the hypothe-
sized pluripotentiality of ARMS. This article outlines the rationale, out-
line and methodological set-up of the On The ROAD study.
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2 | METHODS
2.1 | Design
The design of the study is a naturalistic cohort study of individuals with
ARMS. The present study is implemented in multiple mental health care
centres. The main research centre is the Rob Giel Research center
(RGOc) in Groningen, the Netherlands, a collaborative research centre
of six large mental health care organizations (MHOs) in the North-East
of the Netherlands. A pilot phase of OnTheROAD started in January
2016. During the first period (2016-2018), the main focus was on set-
ting up and implementing the infrastructure for the clinical part of the
Early Detection project (screening, interview and treatment). In 2019,
the official study period for the additional test battery started.
2.2 | Sample
To meet inclusion criteria, individuals need to be aged between
14 and 35 years, newly referred to one of the mental health care insti-
tutes of the participating centres in the North-East of the Netherlands
(MHO Friesland, MHO Drenthe, Dimence Group, Mediant, University
Centre Psychiatry, MHO Lentis and Accare) for the treatment of (non-
psychotic) mental health problems, meeting ARMS criteria and having
provided informed consent. Exclusion criteria are a diagnosis of a cur-
rent psychotic disorder according to the DSM, being unable to fill out
questionnaires and limited command of the Dutch language.
2.3 | Procedure
All new patients aged 14-35 are routinely screened online for precursor
stages of psychotic symptoms with the prodromal questionnaire-16
(PQ-16; Ising et al., 2012). Outcome of the screening procedure does
not influence decisions regarding standard care for other, non-psychotic
mental health complaints. In case of a sum score ≥ 6, the Comprehen-
sive Assessment of At risk Mental States (CAARMS, Yung et al., 2005)
and the Social and Occupational Functioning Assessment Scale (SOFAS,
American Psychiatric Association, 1994) are assessed to determine
ARMS. Based on the CAARMS interview in combination with the
SOFAS, each participant is assigned to one of these three categories:
1. No high risk, no first episode of psychosis
2. ARMS
3. First episode of psychosis
Patients in category 1 continue their regular treatment. Patients in
category 3 are referred to a first-episode treatment program. Category
2 is the target population of OnTheROAD. Individuals with ARMS are
offered evidence-based care (including monitoring and treatment) in
the form of an add-on module on top of their regular treatment. This
evidence-based module is based on cognitive behavioural therapy (CBT)
(French & Morrison, 2004) and is tailored to and routinely offered to
individuals with ARMS. This intervention has been shown to result in
50% reduction of the number of transitions to psychosis (from 20% to
10%) (Van der Gaag et al., 2012; Van der Gaag et al., 2013) and has been
shown to be very cost-effective (Ising et al., 2015).
The ARMS category consists of three subgroups: a group with
(a) APS, (b) brief limited psychotic symptoms (BLIPS) (ie, full-blown psy-
chotic symptoms that resolve spontaneously within a week) and
(c) schizotypal personality or a first-degree relative with psychotic history,
in combination with a drop in functioning (Nelson, Yuen & Yung, 2011;
Yung et al, 1996). All three subgroups are included in OnTheROAD.
After identification of ARMS status, participants are invited to take
part in OnTheROAD by a research assistant during the meeting where
the CAARMS results are discussed. If interested, participants sign a
written consent form. A link to the self-report questionnaires is then
sending to the participant via email; interviewer-rated instruments are
assessed during a face-to-face contact moment. The decision whether
or not to enter OnTheRoad does not have any influence on the type of
treatment that the participant receives or on any other variables. In the
first stage of the project, results are not shared with participants or cli-
nicians who are treating them. After collecting data of N = 100 partici-
pants, to aim is provide personal reports with the scores of the
individual participant compared to the group level scores of the
N = 100 sample that the clinician can discuss with the participant.
Standard care is offered to all participants, regardless of whether
they enter OnTheRoad or not. Those who do enter OnTheROAD are
invited to complete an extra assessment battery consisting of several
self-report questionnaires and interviewer-rated instruments that are
described in section 3.
2.4 | Ethics
Because OnTheROAD does not intervene in regular treatment, the
study was exempted by the Medical Ethical Committee of the University
Medical Centre Groningen (M15.173558). Written informed consent is
asked from all participants older than 18 years for the use of the col-
lected clinical data. For participants between the age of 14 and 18, writ-
ten informed consent is asked from both youngster and parents.
3 | INSTRUMENTS
3.1 | Clinical measures
Both categorical (yes/no diagnosis) and dimensional (continuous
scores consisting of sum scores of all individual items) of multiple psy-
chopathological domains are collected:
3.1.1 | Clinical diagnosis
The mini-SCAN interview, a structured clinical diagnostic interview
(Nienhuis, van de Williger, Rijnders, de Jonge, & Wiersma, 2010), is
assessed by trained research assistants in a face-to-face interview. The
mini-SCAN is a validated (Nienhuis et al., 2010) short version of the
Schedules for Clinical Assessment in Neuropsychiatry (SCAN) (Wing
et al., 1990), covering a wide range of DSM diagnoses. All disorders of
which criteria are met are listed as output at the end of the interview.
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3.1.2 | Psychotic symptoms
Psychotic symptoms are assessed in a two-step procedure: first, the
PQ-16 (Ising et al., 2012) is completed. The PQ-16 consists of 16 self-
rated items that are rated on a two-point scale (true/false) (14 positive
psychotic symptoms and 2 negative symptoms). Items are summed.
The PQ-16 showed good concurrent validity with the interview-based
CAARMS diagnoses. Using a cut-off score of six or more symptoms,
Ising et al. (2012) found a high true positive rate (87%) and high speci-
ficity (87%) when differentiating UHR/psychosis from those with no
CAARMS diagnosis.
When scoring above the pre-set cut-off score of ≥6, the Positive
Symptom Scale of the CAARMS (Yung et al., 2005) interview is
assessed. The CAARMS is a semistructured interview, developed spe-
cifically to determine if an individual meets criteria for ARMS or for
onset of first psychotic disorder, based on assessment of the inten-
sity/severity, frequency/duration, and fluctuation of APS over the
past 12 months. The positive symptom scale that was used consists of
four subscales: (a) unusual thought content; (b) non-bizarre ideas;
(c) perceptual abnormalities; and (d) disorganized speech. Scores for
each subscale are rated on intensity, frequency and duration, pattern
of symptoms and level of distress. The CAARMS has good psycho-
metric properties (Yung et al., 2005).
3.1.3 | Negative symptoms
Negative symptoms are assessed with the Brief Negative Symptom
Scale (BNSS; Kirkpatrick et al., 2011). The BNSS consists of 13 items
that are rated by an interviewer on six subscales (blunted affect, alogia,
asociality, anhedonia and avolition). All items are rated on a seven-point
scale. The BNSS has good psychometric properties as it has shown high
interrater consistency (intraclass correlation coefficient [ICC] = 0.96),
test-retest consistency (r = 0.81 over 1 week) and internal consistency
(alpha = 0.93; all values based on total score). In addition, associations
with instruments assessing positive symptoms and other instruments
assessing negative symptom established the discriminant and concur-
rent validity of the BNSS (Kirkpatrick et al., 2011).
3.1.4 | Mood, Anxiety and Stress
Mood, anxiety and stress are assessed with the Depression, Anxiety
and Stress Scale-21 (DASS-21; Lovibond & Lovibond, 1995). The
DASS-21 consists of 21 self-reported items (seven per domain), rated
on a four-point scale. The DASS-21 has good psychometric properties
in terms of factorial structure, internal consistency and concurrent
validity (Antony, Bieling, Cox, Enns, & Swinson, 1998).
3.1.5 | Mania
Mania is assessed with the self-reported Altman Self-Rating Mania
Scale (ASRM; Altman, Hedeker, Peterson, & Davis, 1997). The
ASRM contains five items covering several symptom domains of
mania (elevated/euphoric mood, increased self-esteem, decreased
need for sleep, pressured speech, and psychomotor agitation). For
each item, five possible statements are given on a five-point range
that represent increasing levels of mania. The ASRM has shown
good psychometric properties in clinical samples, with good test-
retest reliability on a sample of depressed and manic patients, the
ability to assess severity of manic symptoms in patients with
mania and to pick up change following treatment (Altman
et al., 1997).
3.1.6 | Eating disorders
Symptoms of eating disorders are assessed with the SCOFF, a five
item self-report questionnaire that screens for eating disorders
(Morgan, Reid, & Lacey, 1999). The SCOFF addresses core features
of anorexia nervosa and bulimia nervosa: (a) feeling sick or vomiting
after eating; (b) losing control about the amount of feed one eats;
(c) losing more than one stone in 3 months, (d) believing yourself to
be fat and (e) food dominating your life. Items are scored as
yes/no. High levels of reliability and acceptable trade-offs between
sensitivity and specificity have been found for the SCOFF in the orig-
inal as well as translated versions (Botella, Sepúlveda, Huiling, &
Gambara, 2013).
3.1.7 | Problematic behaviour
Aggression and self-harm are assessed using an instrument that was
developed for the European Long-acting Antipsychotics in Schizo-
phrenia Trial study. Three questions were developed, based on other
subscales of several other questionnaires, being the Staff Observation
Aggression Scale-Revised (Nijman et al., 1999), the Modified Overt
Aggression Scale (Kay, Wolkenfield, & Murril, 1988) and the Self Harm
Behaviour Questionnaire (Gutierrez, 1998). These questions cover
whether, during the past month, the participant (a) had deliberately
harmed oneself, (b) had been involved in a violent incident or had
been a victim of violence or (c) had attacked somebody oneself. For-
mal psychometric information is not yet available.
3.1.8 | Somatization
Symptoms of somatization are assessed with the SPHERE-12 (Hickie
et al., 2001), that included 12 self-report items from the original
34-item Somatic and Psychological Health Report (SPHERE) question-
naire. The SPHERE-12 covers six somatic (fatigue, somatic complaints)
and six psychological (depression, anxiety) items on a three-point
Likert scale. Combining the somatic and psychological dimensions can
help to identify those patients with problems on one of these
domains, on neither or on both. This system has shown to have
acceptable validity and reliability (Hickie et al., 2001).
3.1.9 | Alexithymia
Alexithymia, or the inability to identify and describe emotions ade-
quately, is assessed with the Toronto Alexithymia Scale (TAS-20;
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Bagby, Parker, & Taylor, 1994). The TAS-20 consists of 20 self-report
items, subdivided into three subscales: difficulty with describing feel-
ings (five items), difficulty with identifying feelings (seven items) and
externally-oriented thinking (eight items), all rated on a five-point
Likert scale. The TAS-20 was shown to have good internal consistency
and test-retest reliability, as well as a three-factor structure that
matches with the alexithymia construct (Bagby et al., 1994).
3.1.10 | Clinical Global Impression
The Clinical Global Impression-Severity scale (CGI-S; Guy, 1976) is
used to assess overall severity of illness on a seven-point scale. The
interviewer rates the severity of the patient's illness at the time of
assessment, relative to their previous experience with similar patients.
The CGI was shown to have good internal consistency and concurrent
validity in a clinical sample (Leon et al., 1993).
3.2 | Functioning
3.2.1 | SOFAS
Functioning is assessed using the Social and Occupational Functioning
Scale (SOFAS; APA, 1994). The SOFAS is an interview-rated scale that
gives a global assessment of the level of social and occupational func-
tioning. Scores can range between 0 (not functioning at all) and
100 (superior functioning). In scoring the SOFAS, impact of symptoms
is taken into account; therefore, this measure reflects a combination
of symptomatic and functional outcomes. The lowest score in the past
year is used in the current study.
3.2.2 | Global functioning scales
The Global functioning scales (Cornblatt et al., 2007) comprise two
interviewer-rated scales that assess functioning specifically in the
ARMS population: the Global Functioning Social (GF: Social) and the
Global Functioning Role (GF: Role) scales. The two scales are designed
along the lines of the GAF and SOFAS scales, but measure these two
sub-domains separately. In addition, the scales take age and phase of
illness into account. Both scales can be rated on a scale from
1 (severely disabled) to 10 (superior functioning) with each score
described by an anchor. Both scales showed high interrater reliability
and sensitivity to change and preliminary support for construct valid-
ity was also reported by Cornblatt et al. (2007).
3.3 | Background factors
3.3.1 | Demographics
The following demographic information is obtained through self-
report: age, gender, ethnicity, relationship status, living arrangements,
education, employment and sexual orientation.
3.3.2 | Potential risk factors
3.3.3 | Bonding
Bonding is assessed with the inventory for parent and peer attach-
ment (IPPA; Armsden & Greenberg, 1987), a 48-item self-report ques-
tionnaire that asks about bonding to the participant's mother
(or mother figure), father (or father figure) and significant other
(16 items per person). Items are rated on a five-point Likert scale. The
IPPA has shown to have good internal consistency, test-retest reliabil-
ity and good concurrent and divergent validity (Armsden & Greenberg,
1987).
3.3.4 | Life events
Life events are assessed using the List of Threatening Experiences
(LTE; Brugha, Bebbington, Tennant, & Hurry, 1985), a self-report
questionnaire that asks about 12 potential life events that may have
happened during the past year, for example, having experienced seri-
ous illness or loss and that are scored as yes/no. In a clinical popula-
tion, the LTE was shown to have high test-retest reliability and also
good agreement with information from an external informant. Good
concurrent validity was shown with a semi-structured life events
interview (Brugha & Cragg, 1990).
3.3.5 | Trauma
Youth trauma is assessed using the Dutch version of the childhood
trauma questionnaire (CTQ; Bernstein et al., 1994). The CTQ is a
28-item self-report instrument that assesses the experience of five
types of youth trauma (emotional abuse, physical abuse, sexual abuse,
emotional neglect and physical neglect). The extent to which each
type of trauma has been experienced is rated on a five-point Likert
scale. The CTQ has shown high internal consistency, good test-retest
reliability (interval 2-6 months) and good concurrent validity
(Bernstein et al., 1994).
3.3.6 | Discrimination
To assess discrimination, the same items are assessed as in the Transi-
tions study (Purcell et al., 2015), who adapted three questions from a
scale assessing discrimination in the Quality of Life in Newly Diag-
nosed Epilepsy Instrument (NEWQOL; Abetz, Jacoby, Baker, &
McNulty, 2000) battery.
3.3.7 | Family history of mental disorder
Family history of mental disorder is assessed by inquiring whether the
father, mother or sibling(s) of the participant ever had any psychiatric
problems. If yes, further questions on the nature of these problems
and whether professional treatment was sought are probed.
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3.4 | Cognitive functioning
3.4.1 | Neurocognition
Neurocognition is assessed using the Cambridge Neuropsychological
Test Automated Battery (CANTAB, 2017; www.cantab.com). The
CANTAB is a computerized battery of tests that screens several rele-
vant cognitive domains: memory (verbal, working and visual), spatial
planning, strategy, attention flexibility, alertness and motor speed.
This often-used battery has shown to be able to adequately discrimi-
nate between healthy adults and individuals with psychiatric disorders
(Egerhazi, Berecz, Bartok, & Degrell, 2007; Haring, Mottus, Koch,
Trei, & Maron, 2015).
3.4.2 | Social cognition
Social cognition is assessed using the Faux Pas (Stone, Baron-Cohen, &
Knight, 1998). The Faux Pas presents the participant with nine
vignettes describing social situations. The participant is then asked to
answer several written questions to investigate whether they recog-
nized the faux pas in the story. The Faux Pas has shown excellent reli-
ability in a Swedish sample (Söderstrand & Almkvist, 2012).
3.5 | Quality of life
Following the Purcell et al. (2015) transitions study, who, in turn,
followed Murphy, Herrman, Hawthorne, Pinzone, and Evert (2000),
quality of life is assessed with one item from the WHOQOL-100
where participants rated their overall quality of life during the past
4 weeks on a five-point scale.
4 | FOLLOW-UP PROCEDURE
All measures described above are assessed at baseline. The CAARMS
and the SOFAS are then assessed every 3 months for 1 year, follow-
ing standard procedures for treatment of ARMS. Participants are
invited for follow-up assessments after 1, 2 and 2 years when all mea-
surements are re-assessed.
5 | STATISTICAL ANALYSES
Analyses include t-test, Chi-square, Pearson/Spearman correlations,
multiple linear regression and multiple logistic regression. Survival
analysis will be used to predict the onset of psychotic disorder and
other mental disorder, controlling for relevant covariates (including
gender, age, severity of psychopathology, history of mental health
care, familial history of psychopathology). Linear regression will be
used to predict psychosocial outcome, controlling for relevant
covariates. Multinomial logistic regression will be used for more
detailed analyses, such as predicting different categories of functional
outcomes (eg, working, voluntary activities, household occupations).
Dimensional assessments of psychopathology will be transformed
when necessary due to non-normality. Beta coefficients, ORs and
95% confidence intervals will be calculated.
6 | DISCUSSION
This article describes the research protocol of OnTheROAD, a
study in young people at risk for severe mental illness, namely indi-
viduals with ARMS. Although the predictive specificity of ARMS
remains a topic under debate, ARMS is considered a risk factor for
(a) later psychotic disorder, (b) many other psychiatric disorders
and (c) poor psychosocial functioning. Therefore, broader assess-
ment of the developmental course and outcome of ARMS over time
is necessary. The objective of OnTheROAD is to follow a cohort of
individuals with ARMS who receive state-of-the-art care specific
for ARMS, by monitoring the course of ARMS over time and, spe-
cifically, to assess individuals with ARMS from a broader perspec-
tive, by assessing multiple domains of psychopathology,
functioning and factors of risk and resilience. In particular, we are
interested in the role of negative symptoms in ARMS (Wunderink,
2017), in terms of both characterization of ARMS and their predic-
tive value. Results of this study may aid in refining the existing
ARMS criteria and developing more effective and personalized
early interventions.
OnTheROAD joins a larger movement of monitoring ARMS over
time, but also has several innovative aspects. Firstly, it assesses not
only psychotic symptoms as predictors of outcome, but other
potentially relevant symptoms as well. This addresses in more detail
the heterogeneity of ARMS and fits the idea that risk factors can be
pluripotential, predicting a wider range of poor outcome. Secondly,
not only onset of first psychotic disorder is investigated. On the
one hand, the focus on prediction of transition to psychotic disor-
ders as primary outcome of the ARMS trajectory has been shown
to be too narrowly defined (McGorry et al., 2018; Yung et al.,
2012); on the other hand, recent studies again suggest more speci-
ficity of prediction (Fusar-Poli et al., 2017; Woods et al., 2018). This
study will contribute to the ongoing discussion on the specificity of
ARMS for predicting clinical outcome. Thirdly, the study explores a
broader range of conceivable predictors of clinical and functional
outcome besides positive psychotic symptoms, in particular nega-
tive symptoms.
By means of OnTheROAD, we add to a broader development in
the field that examines the pluripotentiality of ARMS. We aim to
improve our understanding of the clinical picture of ARMS by tak-
ing a developmental, broader and transdiagnostic perspective and,
eventually, we hope to improve clinical mental health care by pro-
viding more detailed information of individual patients' psycho-
pathological profiles by combining insights from the clinical staging
model (ie, the developmental stage of illness severity) with more
personalized risk profiles based on context (ie, risk and protective
factors, other patterns of co-occurring psychopathology), so
that provided care can be better matched to individual needs
(Wunderink, 2018).
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Recruitment of participants now takes place in mental health care
services. In the future, we aim to extend recruitment also to General
Practitioners, possibly using different strategies to screen sub-
populations at heightened risk (Boonstra, Wunderink, Sytema, &
Wiersma, 2009). This step will also enable us to study earlier phases
of the clinical staging model, as phases of developing mental illness
that precede ARMS are then also captured.
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